ZYBERNO
Stock Report
Updated Sep 1, 2026

Synergy CHC Corp. (SNYR)

Healthcare • NASDAQ

$0.11

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
Synergy CHC Corp. (SNYR) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-39.6%)
Return on Capital (Capital Efficiency):CRITICAL (-245.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Synergy CHC Corp. (SNYR) stock report — Zyberno Score 9/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.11
Market Cap:$1.22M

Valuation Multiples (2)

P/S Ratio:0.04x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$29.98M

Price Action & Momentum (1)

% of 52-Week High:3.6%
B. Profitability Assessment

Return Metrics (4)

ROA:-110.7%
Reinvestment Rate:1.6%
Fundamental Growth Rate (g):-4.0%

Margin Analysis (3)

Operating Margin Ttm:-39.6%
Net Margin Ttm:-57.0%
Ebitda Margin:-39.1%

TTM Performance (3)

Gross Margin Ttm:65.4%
Operating Margin Ttm:-39.6%
Net Margin Ttm:-57.0%

Yield Metrics (2)

Earnings Yield:-$1.60K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-377.6%
Latest Earnings Filed:2026-05-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-0.2%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):7.1%

Cash Flow Growth (Linear) (1)

Operating Cash Flow Growth Rate (Linear):-5.9%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):9.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.93x
Quick Ratio:0.43x
Cash Ratio:0.04x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.24x
Times Interest Earned:-1.24

Capital Structure (4)

Working Capital:-503,862.00
Cash And Cash Equivalents:292,115.00
Long Term Debt:$25.02M
Net Debt:$28.76M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $27.70M
Linear Growth: -24.0%
📊 Click to view full SNYR Revenue analysis & methodology →
Cost Of Revenue Ttm:$9.59M

Profitability Breakdown (2)

Gross profit TTM: $18.11M
Linear Growth: -68.0%
📊 Click to view full SNYR Gross Profit analysis & methodology →
Operating income TTM: -$10.97M
Linear Growth: 9.8%
📊 Click to view full SNYR Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: -$15.79M
Linear Growth: 7.1%
📊 Click to view full SNYR Net Income analysis & methodology →
Income Before Tax:-$15.67M
Ebitda Ttm:-10,840,238.00

Operating Expenses (5)

Operating Expenses:29,083,163.00
R And D Expense:0.00
Sga Expense:9,571,939.00
Income Tax Expense:$293.86K
Interest Expense:6,836,494.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:174.3%
Ebitda Margin:-39.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.46M
Current Assets:$6.34M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$116.67K

Liability Structure (4)

Total Liabilities:31,866,841.00
Current Liabilities:6,848,786.00
Long Term Debt:$25.02M
Short Term Debt:$4.03M

Equity & Capital (3)

Equity:-$25.41M
Retained Earnings:-$59.01M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:1,268,022.00
Inventory:3,381,614.00
Accounts Payable:4,031,994.00

Special Items (2)

Contract Liabilities:1,526.00
Stock Based Compensation:116,307.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$3.81M
Linear Growth: -5.9%
$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$307.60K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,673,201.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$387.12K

Non-Cash Items (1)

Depreciation Amortization Ttm:133,334.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.60
Eps diluted TTM: -$1.60
Linear Growth: 23.8%
📊 Click to view full SNYR EPS analysis & methodology →
Earnings Per Share Ttm:-$1.40

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.45
Operating Cash Flow Per Share:-$0.23

Book Value & Capital (2)

Book Value Per Share:-$2.25
Cash Per Share:0.03

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.94x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:21.85x
Days Sales Outstanding Ttm:16.71

Inventory Management (2)

Inventory Turnover Ttm:2.84x
Days Inventory Outstanding Ttm:128.66

Payables & Cash Cycle (2)

Days Payable Outstanding:153.41
Cash Conversion Cycle:-8.04
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.6%
Fundamental Growth Rate (g):-4.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):-0.2%
Net Income Growth Rate (Linear):7.1%
Operating Income Growth Rate (Linear):9.8%

Cash Flow Growth Rates (1)

Operating Cash Flow Growth Rate (Linear):-5.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-0.7%
Book Value Growth Rate (Linear):-24.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:SNYR
Company Name:Synergy CHC Corp.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:11.30M
Shares Outstanding Basic:11.30M
Shares Outstanding Diluted:11.30M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 20:35:52 UTC
Data Timestamp:2026-08-22T10:34:51.133890
Scroll to Top